Setting new standards in information exchange for the pharmaceutical and biotech industry
Breast Cancer Renegade Dr Laura Esserman Confirmed as Keynote Speaker at Immuno-Oncology 360° 2019
November 6, 2018
Laura Esserman, MD, MBA, the founder and co-principal investigator for the I-SPY 2 clinical trial delivers a keynote address at the 5th annual Immuno-Oncology 360° Summit taking place February 6-8, 2019 in New York City.
Dr Esserman will discuss the remarkable progress achieved by the I-SPY 2 clinical trial in improving outcomes of breast cancer. She will also explain how I-SPY 2 is impacting oncology beyond breast cancer through increased efficiencies that promise to accelerate the development and delivery of more effective therapies for other cancer types and a range of other diseases. I-SPY 2 is a groundbreaking national public-private collaboration designed to reduce the time and cost for drug development and to use drugs earlier in the disease course.
Dr Esserman is considered a visionary in challenging approaches to cancer screening and a revolutionary in cancer treatment. She has recently been recognized as OncLive®’s 2018 Giant in Cancer Care and received an award for challenging the reigning paradigms in oncology with her innovative and groundbreaking contributions to patient care, clinical practice, and translational research.
For more information about Immuno-Oncology 360˚ visit: https://theconferenceforum.org/conferences/immuno-oncology-360/overview/